Navigation Links
Anthera Pharmaceuticals Names Lawrence Rosania as Vice President of Global Regulatory Affairs and Compliance
Date:2/8/2011

strategy and filings for r-hGH (Norditropin®), targeting a growth deficiency in children indication, and r-FVIIa (NovoSeven®), targeting a hemophilia indication. Mr. Rosania has an M.S. degree in Chemistry from Drexel University and an M.S. degree in Organizational Dynamics from The University of Pennsylvania.

About Anthera Pharmaceuticals

Anthera Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing products to treat serious diseases associated with inflammation, including cardiovascular and autoimmune diseases. Anthera has one Phase 3 clinical program, A-002, and two Phase 2 clinical programs, A-623 and A-001. A-002 and A-001 inhibit a novel enzyme target known as sPLA2. Elevated levels of sPLA2 have been implicated in a variety of acute inflammatory conditions, including acute coronary syndrome and acute chest syndrome, as well as chronic diseases such as stable coronary artery disease (CAD). Anthera's Phase 2 product candidate, A-623, targets elevated levels of B-lymphocyte stimulator (BAFF) which has been associated with a variety of B-Cell mediated autoimmune diseases, including systemic lupus erythematosus (lupus). For more information, please visit www.anthera.com.

Safe Harbor Statement

Certain statements contained in this press release that refer to future events are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on Anthera's expectations as of the date of this press release and are subject to certain risks and uncertainties that could cause actual results to differ materially as set forth in the Company's public filings with the Securities and Exchange Commission, including Anthera's Quarterly Report on Form 10-Q for the quarter ended September 30, 2010. Anthera disclaims any intent or obligation to
'/>"/>

SOURCE Anthera Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Anthera Announces Completion of Enrollment and Dosing in Phase II Trial of A-002 for the Treatment of Cardiovascular Disease
2. Anthera Announces Positive Phase II Clinical Results From A-002 Cardiovascular Disease Trial
3. Antheras A-001 Receives Orphan Drug Status for the Prevention of Acute Chest Syndrome in Patients With Sickle Cell Disease
4. Anthera Announces Preliminary Positive Results From Once-Daily A-002 Phase II Cardiovascular Trial
5. Anthera Enters Into Manufacturing Agreements for Varespladib in Preparation for Pivotal Phase III Trials
6. DSMB Supports Continuation of Anthera Phase II Impacts Trial for the Prevention of Acute Chest Syndrome in Patients With Sickle Cell Disease
7. Anthera Pharmaceuticals Advances Global Development Strategy for Varespladib in Patients With Acute Coronary Syndrome With the Initiation of FRANCIS Trial
8. Anthera Completes Special Protocol Assessment With FDA and Receives EMEA Scientific Advice on Development Path Toward Varespladib Approval
9. Following Encouraging Results Anthera to Continue IMPACTS Trial for the Prevention of Acute Chest Syndrome in Patients With Sickle Cell Disease
10. Antheras Varespladib Meets Primary Endpoint in Phase 2 FRANCIS Trial for the Treatment of Acute Coronary Syndrome
11. Anthera Pharmaceuticals Announces Agreement With the FDA on a SPA for Planned Phase 3 Varespladib A-002 Study; Daniel K. Spiegelman Joins Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)...  Decision Resources Group finds that the Asia Pacific ... China , India , ... through 2023. Dental implant procedure volumes will grow as physicians are ... Other key findings from Decision Resources Group,s coverage of the ... , Dental implant penetration: Penetration of dental implants among the ...
(Date:9/30/2014)... -- Alimera Sciences, Inc. (NASDAQ: ALIM ) (Alimera), ... and commercialization of prescription ophthalmic pharmaceuticals, announced today that ... Technology Growth Capital, Inc. (NYSE: HTGC ) ... under the Loan and Security Agreement that Alimera,s subsidiary ... Sciences Limited, entered into with Hercules in April of ...
(Date:9/30/2014)... 2014 The Chinese wound care market is ... in the incidence of lifestyle diseases, coupled with the ... of better quality of wound care products provide the ... of public health insurance schemes and increased reimbursement rate ... on the findings of primary and secondary researches, this ...
Breaking Medicine Technology:Asia Pacific Dental Implant Market Will Grow at a Strong Rate Through 2023 2Asia Pacific Dental Implant Market Will Grow at a Strong Rate Through 2023 3Alimera Sciences Receives $25 Million Advance from Hercules Technology Growth Capital 2China Wound Care Market 2China Wound Care Market 3
... HAYWARD, Calif., Feb. 1, 2011 Anthera Pharmaceuticals, Inc. ... drugs to treat serious diseases associated with abnormal auto-immune ... Dr. Peter Thompson to its Board of Directors. Currently, ... is the founder and Managing Director of Strategicon Partners, ...
... Mich., Feb. 1, 2011 Stryker Corporation (NYSE: ... previously announced sale of its OP-1 product family, which ... use in orthopaedic bone applications. The transaction also includes ... Stryker is one of the world,s ...
Cached Medicine Technology:Dr. Peter Thompson Joins Anthera Pharmaceuticals Board of Directors 2
(Date:10/1/2014)... Marriagelifeinsurance.com has released a new blog post explaining how ... Senior citizens can purchase a joint life insurance policy ... joint policy is cheaper, but will only pay benefits ... insurance can be used to cover important funeral expenses. ... as the application process is simple and straightforward. ...
(Date:10/1/2014)... Lifeinsurance-policy.com has released a new blog post ... for smokers. , Smoking will always have a negative ... the best method to find affordable coverage. Insurance brokerage ... coverage. , Whole life insurance premiums will be ... the coverage is permanent, the initial rates are ...
(Date:10/1/2014)... ATLANTA (PRWEB) October 01, 2014 ... executive networking and relationship-marketing firm, announced today ... Security Executive® and Project of the Year ... decision makers representing organizations in financial services, ... include large-scale technology endeavors that address key ...
(Date:10/1/2014)... DURHAM, N.C. A new genetic finding from Duke ... hostility, anxiety and depression might also be hard-wired to ... diabetes and heart disease. , An estimated 13 percent ... the genetic susceptibility, and knowing this could help them ... healthy diet, exercise and stress management. , "Genetic susceptibility, ...
(Date:10/1/2014)... Innovations announces the upcoming airing of Innovations with ... 20, 2014 at 7:30 a.m. EST/PT via Discovery Channel. ... scenes to learn about Break the Cycle’s comprehensive dating ... help and information Break the Cycle provides to teens ... abuse, how to navigate the legal system, and provides ...
Breaking Medicine News(10 mins):Health News:Elderly Life Insurance - Find Life Insurance for Retired Couples! 2Health News:Affordable Whole Life Insurance Premiums for Smokers! 2Health News:T.E.N. Announces Nominees for the 2014 ISE® North America Awards; People’s Choice Award voting now open to industry at large 2Health News:T.E.N. Announces Nominees for the 2014 ISE® North America Awards; People’s Choice Award voting now open to industry at large 3Health News:T.E.N. Announces Nominees for the 2014 ISE® North America Awards; People’s Choice Award voting now open to industry at large 4Health News:T.E.N. Announces Nominees for the 2014 ISE® North America Awards; People’s Choice Award voting now open to industry at large 5Health News:T.E.N. Announces Nominees for the 2014 ISE® North America Awards; People’s Choice Award voting now open to industry at large 6Health News:T.E.N. Announces Nominees for the 2014 ISE® North America Awards; People’s Choice Award voting now open to industry at large 7Health News:Gene interacts with stress and leads to heart disease in some people 2Health News:Innovations to Explore Breakthroughs in Health and Wellness in Upcoming Episode Airing Monday, October 20, 2014 via Discovery Channel 2
... ... its new home at the UCSF Mission Bay campus near downtown San Francisco. , ... (Vocus) June 22, 2010 -- UCSF ... new home at the UCSF Mission Bay campus near downtown San Francisco. The gift is ...
... ... Support Initiatives , ... Santa Clara, Calif. (PRWEB) June 22, 2010 -- Aerohive Networks, creators of the ... joined the company as Vice President of Technical Operations. Jiang will report directly to ...
... Physicist David William Townsend will be honoured with the ... for the design, commercial development and clinical implementation of ... medal jointly with his co-inventor, engineer Ronald Nutt, on ... Montreal, Quebec, Canada. IEEE is the world,s largest ...
... Park, MD (June 22, 2010) -- The Human Genome Project, ... of hundreds of animal, plant, fungal, and microbe genomes in ... data with which researchers are struggling to keep pace. Knowing ... that genes play in the actual manifestation of physical traits ...
... ... risk management to be integrated on MetricStream GRC Platform , ... (PRWEB) June 22, 2010 -- SunTrust Banks, ... leader in Governance, Risk, Compliance (GRC) solutions, to integrate audit, compliance and risk ...
... ... the word about HIV prevention. , ... Chicago, IL (PRWEB) June 22, 2010 -- STDTestExpress , a service dedicated to ... HIV test with the purchase of an 8 Test Panel – a savings of $50. The ...
Cached Medicine News:Health News:UCSF Children's Hospital Receives $100 Million Gift To Build New Hospital 2Health News:UCSF Children's Hospital Receives $100 Million Gift To Build New Hospital 3Health News:UCSF Children's Hospital Receives $100 Million Gift To Build New Hospital 4Health News:UCSF Children's Hospital Receives $100 Million Gift To Build New Hospital 5Health News:Aerohive Networks Appoints Dr. Lin Jiang as Vice President of Technical Operations 2Health News:Aerohive Networks Appoints Dr. Lin Jiang as Vice President of Technical Operations 3Health News:A*STAR scientist receives international award for innovation in healthcare technology 2Health News:New genetic analysis reveals principles of phenotypic expression 2Health News:MetricStream Selected by SunTrust for Enterprise-Wide GRC 2Health News:MetricStream Selected by SunTrust for Enterprise-Wide GRC 3Health News:STDTestExpress Highlights National HIV Testing Day with Free HIV Testing 2Health News:STDTestExpress Highlights National HIV Testing Day with Free HIV Testing 3
Adjustable wire speculum with 17 mm open blades. Lid tension adjustable throughout procedure with thumb screw control. Shaft angled 45 degrees. Manufactured in titanium....
Solid 13.5 mm wide by 5 mm deep blades. Edge of blades serrated. Dull finish....
Adjustable lid speculum angled 45 degrees with 17 mm curved solid blades and aspiration ports to remove excess fluid from around the eye during ocular procedures....
Open 11 mm blades. Dull finish. Most popular size or model....
Medicine Products: